Collegium Pharmaceutical, Inc.
NASDAQ:COLLDrug Manufacturers - Specialty & Generic
-$0.24 today
- Market cap
- $805.79M
- Beta
- 0.75
- P/E (TTM)
- 14.3
- EPS (TTM)
- $2.34
Volume 0.49M
Average 0.50M
COLL Short-term Investments
Marketable securities and deposits the company expects to convert to cash within a year.
Collegium Pharmaceutical, Inc.NASDAQ: COLL
Short-term Investments · Q1 FY2026 · quarter ended Mar 2026
Short-term investments rises 50.7% from a year ago
Short-term investments stood at $153.11M at the end of Q1 FY2026, up 50.7% from a year earlier and down 1.5% from the prior quarter.
Context
- Short-term investments amounted to 9.3% of total assets at the end of Q1 FY2026, up 3.0 pp from a year earlier.
- Short-term investments increased in 3 of the last 3 fiscal years.
- FY2025 was the highest annual figure in the 4 fiscal years shown.
What to watch
Whether short-term investments keeps rising in the next quarterly balance sheet after a +50.7% change from a year earlier.
Sources:Balance SheetText generated from reported figures; not investment advice.
Short-term Investments history
USD · from the balance sheet
- Latest · FY2025
- 155.43M USD
- Year-over-year change
- +68.6%
| Period | Period end | Short-term Investments | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 155.43M | +68.6% |
| FY2024 | 2024-12-31 | 92.2M | +28.8% |
| FY2023 | 2023-12-31 | 71.6M | — |
| FY2022 | 2022-12-31 | 0 | — |
| FY2021 | 2021-12-31 | 0 | — |
Short-term Investments vs competitors
How COLL compares with its peers on the latest reported figures
- COLL's Mar 2026 short-term investments of $153.11M is the highest of the 3 companies compared; the peer median is $28.94M.
- Its year-over-year change of +50.7% is the highest of 2, against a peer median of -72.4%.
- Short-term investments amounts to 9.3% of total assets for COLL, versus a peer median of 2.4%.
| Company | Period | Latest balance | YoY | 3-year CAGR | % of assets |
|---|---|---|---|---|---|
| Mar 2026 | $153.11M | +50.7% | — | 9.3% | |
| Mar 2026 | $57.87M | -72.4% | -24.4% | 4.8% | |
| Mar 2026 | $10K | — | — | 0.0% | |
LTGOLatigo Biotherapeutics Inc. | — | — | — | — | — |
| Peer median (excluding COLL) | $28.94M | -72.4% | -24.4% | 2.4% | |
Competitors are the stored peer set for COLL. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Balance Sheet
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Cash & Equivalents | 186.43M | 173.69M | 238.95M | 70.57M | 251.1M |
| Short-term Investments | 0 | 0 | 71.6M | 92.2M | 155.43M |
| Net Receivables | 105.84M | 183.12M | 179.53M | 228.54M | 211.33M |
| Inventory | 17.39M | 46.5M | 32.33M | 35.56M | 40.91M |
| Other Current Assets | 27K | 57K | 93K | 27.74M | 3.24M |
| Total Current Assets | 315.54M | 419.99M | 537.6M | 482.26M | 691.41M |
| Property, Plant & Equipment (Net) | 27.14M | 26.38M | 22.01M | 20.15M | 16.2M |
| Goodwill | 0 | 133.7M | 133.86M | 162.33M | 145.93M |
| Intangible Assets | 268.72M | 567.47M | 421.71M | 891.4M | 669.51M |
| Long-term Investments | 2.55M | 0 | 0 | 0 | 1.06M |
| Tax Assets | 78.04M | 23.95M | 26.26M | 98.03M | 112.54M |
| Other Non-current Assets | 87K | 2.65M | 1.87M | 9.42M | 20.19M |
| Total Non-current Assets | 376.53M | 754.14M | 605.71M | 1.18B | 965.42M |
| Total Assets | 692.08M | 1.17B | 1.14B | 1.66B | 1.66B |
| Account Payables | 4.19M | 3.49M | 8.69M | 3.93M | 10.66M |
| Short-term Debt | 48.35M | 162.5M | 183.33M | 64.58M | 30.41M |
| Tax Payables | 3.19M | 4.35M | 7.15M | 15.19M | 0 |
| Deferred Revenue | 0 | 0 | 988K | 0 | 667K |
| Other Current Liabilities | 851K | 1.51M | 253.91M | 7.61M | 378.73M |
| Total Current Liabilities | 279.57M | 433.73M | 457.92M | 509.51M | 440.03M |
| Long-term Debt | 201.63M | 538.45M | 483.84M | 787.91M | 906.02M |
| Deferred Tax Liabilities | 0 | 0 | 0 | 0 | 0 |
| Deferred Revenue (Non-current) | 0 | 0 | 0 | 10M | 9.11M |
| Other Non-current Liabilities | 0 | 0 | 0 | 121.8M | (4.13M) |
| Total Non-current Liabilities | 209.58M | 545.56M | 489.96M | 925.24M | 915.13M |
| Total Liabilities | 489.15M | 979.29M | 947.88M | 1.43B | 1.36B |
| Common Stock | 36K | 37K | 38K | 40K | 41K |
| Retained Earnings | (256.34M) | (281.34M) | (233.19M) | (164M) | (101.13M) |
| Accumulated OCI | 0 | 0 | 14K | 55K | 319K |
| Other Stockholders Equity | 0 | 0 | 0 | 0 | 0 |
| Minority Interest | 0 | 0 | 0 | 0 | 0 |
| Total Equity | 202.93M | 194.84M | 195.43M | 228.84M | 301.68M |
| Total Debt | 258.75M | 709.18M | 674.28M | 859.3M | 940.56M |
| Net Debt | 72.32M | 535.49M | 435.34M | 788.73M | 689.46M |
Collegium Pharmaceutical, Inc.
NASDAQ:COLL
Intrinsic Alpha fair value
Locked
Current Price
$25.93
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.